Source: Annual Congress 2012 - Pathophysiological mechanisms in disease: new insights
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Pisani, A. Onofri, A. Ricotta, F. M. Cauti, A. Ricci, P. Bruno, G. Viola, D. Magrì, S. Mariotta (Rome, Bologna, Italy). NT-proANP and lung diffusion in sarcoidosis. Eur Respir J 2012; 40: Suppl. 56, 242

Member's Comments

No comment yet.

Related content which might interest you: Diffusing lung capacity and pro-brain natriuretic peptide in patients with limited cutaneous form of systemic sclerosis at risk for pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Serum and pleural albumin gradient and brain natriuretic peptide (BNP) levels in the diagnosis of cardiac and non-cardiac pleural effusions Source: Annual Congress 2008 - Pleural effusion Year: 2008 Clinical utility of pleural fluid NT-pro-brain natriuretic peptide (NT-proBNP) in patients with pleural effusions Source: Eur Respir J 2006; 28: Suppl. 50, 580s Year: 2006 Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 111s Year: 2004 Prognostic value of serum N-terminal brain natriuretic peptide type B for pulmonary hypertension among patients with usual interstitial pneumonia and sarcoidosis Source: Annual Congress 2007 - Pulmonary vascular involvement in smoking and respiratory diseases Year: 2007 Elevated brain natriuretic peptide predicts mortality in interstitial lung disease Source: Eur Respir J 2010; 36: 819-825 Year: 2010 The pathomechanism of lung fibrosis and sarcoidosis Source: International Congress 2015 – PG17 Lung fibrosis and sarcoidosis Year: 2015 The pathomechanism of lung fibrosis and sarcoidosis Source: International Congress 2016 – PG6 Lung fibrosis and sarcoidosis Year: 2016 High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions Source: Eur Respir J 2006; 28: 144-150 Year: 2006 CPET in interstitial lung disease Source: ERS Skills course - Clinical exercise testing: advanced Year: 2018 The diagnostic value of N-terminal pro-C-type natriuretic peptide in COPD patients with pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Measurement of lung diffusion in obstructive lung disease Source: Annual Congress 2004 - PG13 - Lung diffusion measurements in diseases Year: 2004 Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Brain natriuretic peptide (BNP) and right ventricular dysfunction predict survival in interstitial lung disease (ILD) Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease Year: 2008 proBNP is not elevated in patients with advanced COPD and normal left cardiac function Source: Eur Respir J 2007; 30: Suppl. 51, 707s Year: 2007 Oxygen enhanced MRI biomarkers of lung function in interstitial lung disease Source: Virtual Congress 2020 – Quantitative imaging in diffuse lung disease Year: 2020 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism Source: Eur Respir J 2003 Oct 01;22(4):649-653 Year: 2003 Comparison of NT-proBNP and BNP in the diagnosis of pulmonary hypertension – influence of renal impairment Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004